Press release
cerbomed gets CE labeling for transcutaneous vagus nerve stimulator
This milestone in the certification of the young enterprise clears the way for marketing and sales in the 25 EU member states. The transcutaneous vagus nerve stimulator, developed by cerbomed, is the first and only device with a CE label for transcutaneous vagus nerve stimulation (t-VNS®). It is approved for treating depression and epilepsy, and is an innovative alternative therapy for affected patients.
"We are proud to have received the CE label. This is an essential step preparing the market launch of our innovation,” says Dr. Andreas Hartlep, Chief Technology Officer (CTO) at cerbomed.
The CE label of a product shows that it meets the strict quality, design and performance standards required by EU guidelines for all medical products sold in Europe. cerbomed gmbh obtained the CE label after a comprehensive audit of its product design dossier, and data from clinical trials, as well as the successful completion of an inspection of its facilities.
About cerbomed:
cerbomed is a young, medical device company focusing on the research, development and manufacturing of innovative technologies and products in the area of neurostimulation. Its major proprietary procedure, transcutaneous vagus nerve stimulation (t-VNS®), will offer a new, alternative treatment for various neuropsychiatric disorders with clinical benefit and improved quality of life at a superior cost benefit ratio.
Since its foundation in December 2005, cerbomed has received many innovation and new enterprise prices (including university- and chamber of commerce new enterprise awards), and was among the federal winners of the German new enterprise prize in 2006.
Contact
cerbomed gmbh
Dr. Martin Hyca
Marketing Director
Henkestrasse 91
91052 Erlangen
Phone: +49 (0) 9131 9202 760
Mail: martin.hyca@cerbomed.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release cerbomed gets CE labeling for transcutaneous vagus nerve stimulator here
News-ID: 131553 • Views: …
More Releases from cerbomed gmbh
Pharmaceuticals and medical technology will go hand in hand in future – DESITI …
ERLANGEN/HAMBURG, September 17th, 2015 – The medical technology company cerbomed GmbH from Erlangen and the pharmaceutical company DESITIN Arzneimittel GmbH from Hamburg have entered into a groundbreaking distribution agreement: DESITIN has been granted exclusive distribution rights in Germany by cerbomed for the transcutaneous vagus nerve stimulator NEMOS for treatment of epilepsy.
The successful medium-sized independent company DESITIN has been a specialist provider and proficient partner to doctors and patients in the…
transcutaneous Vagus Nerve Stimulation for epilepsies now available in Norway
ERLANGEN/DRAMMEN, May 28th, 2015 – To address the Norwegian market with transcutaneous Vagus Nerve Stimulation (t-VNS), the medical device company cerbomed from Erlangen, Germany, is cooperating with an experienced distribution partner: Scan-Med A/S from Drammen, Norway.
The company, founded in 1982, considers itself as a connecting link between manufacturers of medical devices and hospitals, as well as health institutions and specialized on distribution service and support of medical equipment.
“We are…
Vagus nerve stimulation without surgery now available in Denmark, Finland and Sw …
ERLANGEN/AALBORG, Mai 28th, 2015 – More than 30 percent of all epilepsy patients still suffer from continued occurrence of seizures, despite appropriate treatment with anticonvulsive drugs. For these patients, only few treatment alternatives are available at the moment. One promising therapy option is transcutaneous Vagus Nerve Stimulation (t-VNS), now also available for patients in Denmark, Sweden and Finland. This has been made possible by cerbomed‘s new distributor Cephalon A/S.…
Trial results for transcutaneous Vagus Nerve Stimulation in pharmacoresistant ep …
ERLANGEN/DRESDEN, 30th April 2015 – At the 9th annual joint conference of the three German-speaking regions of the International League Against Epilepsy in Dresden, the results of a trial on transcutaneous Vagus Nerve Stimulation (t-VNS) in pharmacoresistant epilepsy were presented for the first time.
Trial shows reduction in seizures with t-VNS
In the multi-centre, randomised, controlled, 2-arm, double-blind study, 76 adult epilepsy patients from Germany and Austria were treated over 5…
More Releases for Erlangen
An alternative cancer treatment: Extracorporal Modified Immune Therapy (EMIT)
EMIT is based on the special cultivation of somatic tumor cells and leucocytes of patients, it would be subject to such regulation, too. Due to such financial and administrative obstacles it is almost impossible to offer this promising treatment for public use. If a physician acts against these regulations, this would be regarded as an indictable offence as mentioned above.
Moreover, other problems emerge: Those who do not belong to academic…
Cerbomed GmbH at the 11th European Congress on Epileptology in Stockholm
ERLANGEN/STOCKHOLM, 30.06.2014 – From June 30th until July 3rd 2014 the medical device company cerbomed GmbH from Erlangen, Germany, will present a further therapy option for people suffering from epilepsies at the 11th European Congress on Epileptology in Stockholm: The transcutaneous Vagus Nerve Stimulation (t-VNS) with the therapy device NEMOS.
About t-VNS with NEMOS
Transcutaneous Vagus Nerve Stimulation with NEMOS offers a further therapy option to epilepsy…
Cerbomed GmbH at the 30th International Congress of Clinical Neurophysiology
ERLANGEN/BERLIN, 13.03.2014 – From March 19th until 23rd 2014 the medical device company cerbomed GmbH from Erlangen, Germany, will present the transcutaneous Vagus Nerve Stimulation (t-VNS) at the 30th International Congress of Clinical Neurophysiology.
Please save March 21st and use the chance to get additional information about t-VNS at the Lunch Symposium “Transcutaneous Vagus Nerve Stimulation (t-VNS). Treatment option in epilepsy and pain.” from 12:15 to 13:45 p.m.
About…
Cerbomed at the INS 11th World Congress in Berlin
ERLANGEN/BERLIN, Germany, June 6th 2013 – Between June 9th and 12th, 2013, the German medical device company cerbomed GmbH will present another therapy option for people suffering from hard-to-treat neurological and psychiatric diseases at the 11th world congress of the International Neuromodulation Society in Berlin:
transcutaneous Vagus Nerve Stimulation (t-VNS).
About t-VNS
The t-VNS offers a therapy option for patients suffering from epilepsies, depression or pain.
This therapy uses…
Cerbomed GmbH at the 86th Congress of the German Society of Neurology
ERLANGEN/DRESDEN, Germany, September 12th, 2013 – At the 86th congress of the German Society of Neurology in Dresden the medical device company cerbomed GmbH, Erlangen, Germany, will present a further therapy option for patients suffering from hard-to-treat neurological and psychiatric illnesses: Between September 18th and 21st participants will get first-hand information about the transcutaneous Vagus Nerve Stimulation (t-VNS).
About t-VNS
The t-VNS offers a therapy option for patients suffering from epilepsies,…
Cerbomed GmbH presents transcutaneous Vagus Nerve Stimulation at the 8th annual …
ERLANGEN/BERLIN, Germany, November 20th, 2012 – Between November 23rd and 24th, 2012 the medical device company cerbomed GmbH, Erlangen, Germany will present the transcutaneous Vagus Nerve Stimulation (t-VNS) at the 8th annual meeting of the German Society of Neuromodulation.
Participants will get first-hand information about the new therapy option for patients suffering from difficult-to-treat epilepsies, depression and pain at the booth and in the course of a symposium on November…
